KKR Genetic Disorder GP LLC
CIK 1780428 · last filed 2024-09-17
KKR Genetic Disorder GP LLC is a corporate insider who has filed 2 SEC Form 4 insider transactions across 1 company since 2021. The most recent filing shows the insider sold $1.34B of BBIO on Sep 17, 2024. Across all open-market trades the lifetime net is −$3.01B, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.83B across reported positions. The firm reports its address in New York, NY. 7 SEC filings were submitted jointly with BridgeBio Pharma, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.83B
1
2
-$3.01B
Filer Profile
9 WEST 57TH STREET, SUITE 4200
NEW YORK, NY 10019
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BBIO | 10%+ Owner | 25,260,971 | $72.44 | $1.83B | -$3.01B | 2 | 2024-09-17 |
Recent Filings
2 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-09-17 | BBIO | Sell (S) | −52,200,000 | -$1.34B | EDGAR |
| 2021-02-17 | BBIO | Sell (S) | −27,600,000 | -$1.67B | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.